The use of Scaffold-free cell sheet technique to refine mesenchymal stromal cell-b...
| Full text | |
| Author(s): |
Nadia de Cassia Noronha, N. C.
[1, 2]
;
Mizukami, Amanda
[1]
;
Caliari-Oliveira, Carolina
[3]
;
Cominal, Jucara Gastaldi
[1, 2]
;
Rocha, Jose Lucas M.
[1, 4]
;
Covas, Dimas Tadeu
[1]
;
Swiech, Kamilla
[5, 1]
;
Malmegrim, Kelen C. R.
[1, 6]
Total Authors: 8
|
| Affiliation: | [1] Univ Sao Paulo, Ribeirao Preto Med Sch, Reg Blood Ctr Ribeirao Preto, Ctr Cell Based Therapy, Ribeirao Preto - Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Grad Program Biosci & Biotechnol, Ribeirao Preto - Brazil
[3] In Situ Cell Therapy, SUPERA Innovat & Technol Pk, Sao Paulo - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Grad Program Basic & Appl Immunol, Ribeirao Preto - Brazil
[5] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Ribeirao Preto - Brazil
[6] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ave Cafe S-N, BR-14010903 Ribeirao Preto, SP - Brazil
Total Affiliations: 6
|
| Document type: | Review article |
| Source: | STEM CELL RESEARCH & THERAPY; v. 10, MAY 2 2019. |
| Web of Science Citations: | 1 |
| Abstract | |
Multipotent mesenchymal stromal cells (MSC) have been widely explored for cell-based therapy of immune-mediated, inflammatory, and degenerative diseases, due to their immunosuppressive, immunomodulatory, and regenerative potentials. Preclinical studies and clinical trials have demonstrated promising therapeutic results although these have been somewhat limited. Aspects such as low in vivo MSC survival in inhospitable disease microenvironments, requirements for ex vivo cell overexpansion prior to infusions, intrinsic differences between MSC and different sources and donors, variability of culturing protocols, and potency assays to evaluate MSC products have been described as limitations in the field. In recent years, priming approaches to empower MSC have been investigated, thereby generating cellular products with improved potential for different clinical applications. Herein, we review the current priming approaches that aim to increase MSC therapeutic efficacy. Priming with cytokines and growth factors, hypoxia, pharmacological drugs, biomaterials, and different culture conditions, as well as other diverse molecules, are revised from current and future perspectives. (AU) | |
| FAPESP's process: | 13/08135-2 - CTC - Center for Cell-Based Therapy |
| Grantee: | Dimas Tadeu Covas |
| Support type: | Research Grants - Research, Innovation and Dissemination Centers - RIDC |